Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Keratosis, Actinic 2Bowen's Disease 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × SR-T100 × Clear all
NCT01516515 2018-12-05

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

G&E Herbal Biotechnology Co., LTD

Phase 2 Completed
86 enrolled
Dermatologic

Keratosis, Actinic

NCT02085395 2014-03-14

AK

G&E Herbal Biotechnology Co., LTD

Phase 2 Completed
27 enrolled
Dermatologic

Bowen's Disease, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡